1. Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006; 47: 1987–1996.
2. Hillege HL, Nitsch D, Pfeffer MA et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113: 671–678.
3. Smilde TD, Hillege HL, Navis G et al. Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. Am Heart J 2006; 148: 165–172.
4. Ronco C, McCullough P, Anker SD et al. Cardio--renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010; 31: 703–711.
5. Smilde TD, van Veldhuisen DJ, Navis G et al. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 2006; 15: 1572–1580.
6. Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004; 43: 61–67.
7. Krumholz HM, Chen YT, Vaccarino V et al. Correlates and impact on outcomes of worsening renal function in patients ≥ 65 years of age with heart failure. Am J Cardiol 2000; 85: 1110–1113.
8. Cowie MR, Komajda M, Murray-Thomas T et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006; 27: 1216–1222.
9. Abdel-Qadir HM, Tu JV, Yun L et al. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 2010; 160: 264–271.
10. Ahmed A, Young JB, Love TE et al. A propensity--matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 2008; 125: 246–253.
11. Berger AK, Duval S, Manske C et al. Angiotensin--converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease. Am Heart J 2007; 153: 1064–1073.
12. Ahmed A, Centor M, Weaver MT et al. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications. Am Heart J 2005; 149: 737–743.
13. Massie BM, Armstrong PW, Cleland JG et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. Arch Intern Med 2001; 161: 165–171.
14. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685–693.
15. Comper WD, Hilliard LM, Nikolic-Paterson DJ et al. Disease-dependent mechanisms of albuminuria. Am J Physiol Renal Physiol 2008; 295: F1589–F1600.
16. Gansevoort RT, de Jong PE. The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol 2009; 20: 465–468.
17. Anand IS, Bishu K, Rector TS et al. Proteinuria, chronic kidney disease, and the effect on an angiotensin receptor blocker in addition to an angiotensin--converting enzyme inhibitor in patients with moderate to severe heart failure. Circulation 2009; 120: 1577–1584.
18. Masson S, Latini R, Milani V et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart failure trial. Circulation Heart Failure 2010; 3: 65–72.
19. Arnlöv J, Evans JC, Meigs JB et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham heart study. Circulation 2005; 112: 969–975.
20. Tonelli M, Jose P, Curhan G et al. Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. BMJ 2006; 332: 1426.
21. Jackson CE, Soloman SD, Gerstein et al. Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 2009; 374: 543–550.
22. Groenveld HF, Januzzi JL, Damman K et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52: 818–827.
23. McClellan W, Aronoff L, Bolton K et al. The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin 2004; 20: 1501–1510.
24. Nurko S. Anemia in chronic kidney diseases: causes, diagnosis, treatment. Cleve Clin J Med 2006; 73: 289–297.
25. Opasich C, Cazzola M, Scelsi L et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Heart J 2005; 26: 2232–2237.
26. Anand IS, Rector T, Deswal A. Relationship between proinflammatory cytokines and anemia in heart failure. Eur Heart J 2006; 27 (Suppl 1): 485.
27. Anand IS. Anemia and chronic heart failure implications and treatment options. J Am Coll Cardiol 2008; 52: 501–511.
28. Volpe M, Tritto C, Testa U et al. Blood levels of erythropoietin in congestive heart failure and correlation with clinical, hemodynamic, and hormonal profiles. Am J Cardiol 1994; 74: 468–473.
29. Go AS, Yang J, Ackerson LM et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: outcomes and resource utilization (ANCHOR) study. Circulation 2006; 113: 2713–2723.
30. Kazory A, Ross EA. Anemia: the point of convergence or divergence for kidney disease and heart failure? J Am Coll Cardiol 2009; 53: 639–647.
31. Komajda M, Anker SD, Charlesworth et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006; 27: 1440–1446.
32. Felker GM, Shaw LK, Stough WG et al. Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006; 151: 457–462.
33. Walker AM, Schneider G, Yeaw J et al. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. J Am Soc Nephrol 2006; 17: 2293–2298.
34. You JJ, Austin PC, Alter DA et al. Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am Heart J 2007; 153: 462–470.
35. Tsutamoto T, Kawahara C, Yamaji M et al. Relationship between renal function and serum cardiac troponin T in patients with chronic heart failure. Eur J Heart Fail 2009; 11: 653–658.
36. Sharma R, Gaze DC, Pellerin D et al. Cardiac structural and functional abnormalities in end stage renal disease patients with elevated cardiac troponin T. Heart 2006; 92: 804–809.
37. Khan NA, Hemmelgarn BR, Tonelli M et al. Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis. Circulation 2005; 112: 3088–3096.
38. Maisel A, Mueller C, Adams K Jr et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824–839.
39. Doust JA, Pietrzak E, Dobson A et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systemic review. BMJ 2005; 330: 625–627.
40. Cleland JG, Taylor J, Tendera M. Prognosis in heart failure with a normal ejection fraction. N Engl J Med 2007; 357: 829–830.
41. Niizuma S, Iwanaga Y, Yahata T et al. Impact of left ventricular end-diastolic wall stress on plasma B-type natriuretic peptide in heart failure with chronic kidney disease and end-stage renal disease. Clin Chem 2009; 55: 1347–1353.
42. Bruch C, Fischer C, Sindermann J et al. Comparison of the prognostic usefulness of N-terminal pro--brain natriuretic peptide in patients with heart failure with versus without chronic kidney disease. Am J Cardiol 2008; 102: 469–474.
43. Anwaruddin S, Lloyd-Jones DM, Baggish A et al. Renal function, congestive heart failure, and amino--terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Am Coll Cardiol 2006; 47: 91–97.
44. Damman K, Van Veldhuisen DJ, Navis G et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart 2010; 96: 1297–1302.
45. Lassus J, Harjola VP, Sund R et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007; 28: 1841–1847.
46. Yigla M, Nakhoul F, Sabag A et al. Pulmonary hypertension in patients with end-stage renal disease. Chest 2003; 123: 1577–1582.
47. Yigla M, Abassi Z, Reisner SA et al. Pulmonary hypertension in hemodialysis patients: an unrecognized threat. Semin Dial 2006; 19: 353–357.